



Prevalence of Age-Related Macular Degeneration in Europe

The Past and the Future

Johanna M. Colijn, MD, MSc,^{1,2,*} Gabriëlle H.S. Buitendijk, MD, MSc,^{1,2,*} Elena Prokofyeva, MD, PhD,^{3,4} Dalila Alves, MSc,⁷ Maria L. Cachulo, MD,^{5,6,7} Anthony P. Khawaja, PhD,^{8,9} Audrey Cougnard-Gregoire, PhD,¹⁰ Bénédicte M.J. Merle, PhD,¹⁰ Christina Korb, MD, PhD,¹¹ Maja G. Erke, MD, PhD,¹³ Alain Bron, MD, PhD,¹⁴ Eleftherios Anastasopoulos, MD,¹⁵ Magda A. Meester-Smoor, PhD,^{1,2} Tatiana Segato, MD, PhD,¹⁸ Stefano Piermarocchi, MD, PhD,¹⁸ Paulus T.V.M. de Jong, MD, PhD,^{2,19} Johannes R. Vingerling, MD, PhD,¹ Fotis Topouzis, MD, PhD,¹⁵ Catherine Creuzot-Garcher, MD, PhD,¹⁴ Geir Bertelsen, MD, PhD,¹² Norbert Pfeiffer, MD, PhD,¹¹ Astrid E. Fletcher, PhD,²⁰ Paul J. Foster, MD, PhD,^{9,16} Rufino Silva, MD, PhD,^{5,6,7} Jean-François Korobelnik, MD, PhD,^{10,17} Cécile Delcourt, PhD,¹⁰ Caroline C.W. Klaver, MD, PhD,^{1,2,21} for the EYE-RISK consortium,[‡] and the European Eye Epidemiology (E3) consortium[§]

Purpose: Age-related macular degeneration (AMD) is a frequent, complex disorder in elderly of European ancestry. Risk profiles and treatment options have changed considerably over the years, which may have affected disease prevalence and outcome. We determined the prevalence of early and late AMD in Europe from 1990 to 2013 using the European Eye Epidemiology (E3) consortium, and made projections for the future.

Design: Meta-analysis of prevalence data.

Participants: A total of 42 080 individuals 40 years of age and older participating in 14 population-based cohorts from 10 countries in Europe.

Methods: AMD was diagnosed based on fundus photographs using the Rotterdam Classification. Prevalence of early and late AMD was calculated using random-effects meta-analysis stratified for age, birth cohort, gender, geographic region, and time period of the study. Best-corrected visual acuity (BCVA) was compared between late AMD subtypes; geographic atrophy (GA) and choroidal neovascularization (CNV).

Main Outcome Measures: Prevalence of early and late AMD, BCVA, and number of AMD cases.

Results: Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1%–5.0%) in those aged 55–59 years to 17.6% (95% CI 13.6%–21.5%) in those aged ≥85 years; for late AMD these figures were 0.1% (95% CI 0.04%–0.3%) and 9.8% (95% CI 6.3%–13.3%), respectively. We observed a decreasing prevalence of late AMD after 2006, which became most prominent after age 70. Prevalences were similar for gender across all age groups except for late AMD in the oldest age category, and a trend was found showing a higher prevalence of CNV in Northern Europe. After 2006, fewer eyes and fewer ≥80-year-old subjects with CNV were visually impaired ($P = 0.016$). Projections of AMD showed an almost doubling of affected persons despite a decreasing prevalence. By 2040, the number of individuals in Europe with early AMD will range between 14.9 and 21.5 million, and for late AMD between 3.9 and 4.8 million.

Conclusion: We observed a decreasing prevalence of AMD and an improvement in visual acuity in CNV occurring over the past 2 decades in Europe. Healthier lifestyles and implementation of anti-vascular endothelial growth factor treatment are the most likely explanations. Nevertheless, the numbers of affected subjects will increase considerably in the next 2 decades. AMD continues to remain a significant public health problem among Europeans. *Ophthalmology* 2017;124:1753-1763 © 2017 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Supplemental material available at www.aaojournal.org.

Age-related macular degeneration (AMD) can cause irreversible blindness and is the leading cause of visual impairment in the elderly of European ancestry.¹ Two stages are known for this disease: early AMD, which is

characterized by drusen and pigmentary changes, and late AMD, which can be distinguished in 2 subtypes—geographic atrophy (GA) and choroidal neovascularization (CNV).²

Worldwide estimates approximated that 30–50 million people are affected by AMD,^{3,4} and these numbers are expected to increase over time because of the aging population.^{1,5–9} Although multiple small studies have assessed the prevalence of AMD and its relation to visual decline at various places in Europe,^{10–12} a clear overview for Europe as a whole is lacking.¹³ Comprehensive epidemiologic figures on AMD in Europe would help proper planning for public health and eye care policy makers.

Recent studies report a decrease in AMD-associated blindness and visual impairment,^{14,15} which are likely to be attributable to improved diagnostic procedures and hence earlier diagnosis, and the introduction of anti-vascular endothelial growth factor (VEGF) therapy.^{14–16} Anti-VEGF therapy for CNV was introduced in 2004 and, since 2006, it has been widely used for clinical care in Europe.^{17,18} However, the impact of anti-VEGF therapy on general visual function of persons with AMD in Europe has not been sufficiently studied.^{1,16}

In this study, we investigated the prevalence of both early and late AMD in Europe using summary data of population-based cohort studies from the European Eye Epidemiology (E3) consortium. We analyzed changes in prevalence over time, compared geographic regions, and studied differences between men and women. Moreover, we analyzed the visual acuity of affected individuals before and after the introduction of anti-VEGF therapy and predicted the number of persons with AMD by 2040 in Europe.

Methods

Study Population

Fourteen population-based cohort studies participating in the E3 consortium contributed to this analysis. This consortium consists of European studies with epidemiologic data on common eye disorders; a detailed description on the included studies has been published elsewhere.¹⁶ For the current analysis, studies with gradable macular fundus photographs ($n = 42\,080$ participants) and participants aged 40 years and over provided summary data. Participants were recruited between 1990 and 2013 from the following countries: Estonia, France, Germany, Greece, Italy, Northern Ireland, Norway, Netherlands, Spain, Portugal,^{19,20} and the United Kingdom (UK)¹⁶ (Table 1). The composition of AMD in each cohort is shown in Figure 1 (available at www.aajournal.org). The study was performed in accordance with the Declaration of Helsinki for research involving human subjects and the good epidemiologic practice guideline.

Grading of Age-Related Macular Degeneration

Both eyes of each participant were graded and classified separately by experienced graders or clinicians, and the most severe AMD grade of the worse eye was used for classification of the person. To harmonize classification of AMD, studies were graded or reclassified according to the Rotterdam Classification, as previously described.²¹ Main outcomes of this study were early AMD (grade 2 or 3 of the Rotterdam Classification) and late AMD (grade 4 of the Rotterdam Classification). Persons with late AMD were stratified as GA and CNV or mixed (both GA and CNV present in one person, either both types in the same eye or one type per eye),

which is henceforth in this article referred to as CNV. The Tromsø Eye Study, the Thessaloniki Eye Study, and the European Prospective Investigation into Cancer and Nutrition (EPIC) study had fundus photograph grading that could not be converted to match the definition of early AMD of the Rotterdam Classification. Therefore, these 3 studies only participated in the late AMD analysis.

Visual Impairment

Visual acuity was measured for each eye separately as best-corrected visual acuity in 2 categories: ≥ 0.3 and < 0.3 . When best-corrected visual acuity differed in the 2 eyes, visual acuity of the best eye was used to classify the person. Low vision and blindness were defined as visual acuity < 0.3 and further referred to as visually impaired.

Projection of Age-Related Macular Degeneration

The projection of AMD cases in Europe from 2013 to 2040 was calculated using the prevalence data for 5-year age categories obtained from the meta-analysis. Two different scenarios were used to calculate the projection. In the first scenario, it was assumed that the prevalence of both early and late AMD will remain stable until 2040. This scenario accounted for changes in population structure only. The second scenario followed the trend of decreasing prevalence based on data from the meta-analysis of the E3 consortium regarding the period 2006–2013. We calculated the rate of decline, with 2013 as the starting point and 2040 as the end point, and made the assumption that the rate of decline was decelerating and zero at the end point. For each projected year, prevalences were calculated for every 5-year age group, for early AMD from 45 years of age and onward and for late AMD 65 years and onward. The projected prevalences were then multiplied by the predicted European population estimates obtained from Eurostat for all 28 countries in Europe, and the sum of individuals from all age groups was calculated.²²

Statistical Analysis

The crude prevalence of early and late AMD were calculated per study for each 5-year age group. A random-effects meta-analysis was performed by weighing the studies according to sample size, for early and late AMD separately for 5-year age groups and for people aged 70 years and older. In case of reported zero prevalence, the Haldane correction was used.²³ In the case of 100% prevalence, 0.01 was subtracted to prevent exclusion from the analysis. This analysis was repeated, stratified for the midpoint year of the study recruitment period, before and after the year 2006 and for 10-year birth cohorts. Furthermore, it was repeated for gender, and for geographical area in Europe based on the United Nations Geoscheme.²⁴ A chi-square test was used to compare time trends.

In addition, a meta-analysis was performed for eyes with visual impairment owing to late AMD, and per subtype of late AMD. Subsequently, the analysis was stratified for studies conducted before and after 2006, for which the midpoint year of the study recruitment period was used. The number of visually impaired people was calculated before and after 2006. Meta-analysis was performed with Stata software (release 13, version 13.1; StataCorp LP, College Station, TX) using metaprop. Graphical outputs were constructed with GraphPad Prism 7 (for Windows; GraphPad Software, La Jolla, CA; www.graphpad.com).

Table 1. Description of the European Eye Epidemiology Consortium Studies Included in the Meta-analysis

Region	Study	Data Collection Period	Total Participants (n)	Age Range (yrs)	Median Age (yrs)	Male Gender (%)	European Ethnicity (%)	Crude Prevalence of Early AMD (%)	Crude Prevalence of Late AMD (%)
North	United Kingdom	EPIC	5344	45–85+	60–64	43.1	99.7	–	0.5
	Norway	Tromsø	2631	65–85+	65–69	42.5	91	–	3.5
West	France	ALIENOR-3C	879	70–85+	75–79	37.7	–	16.8	5.6
	Germany	GHS	3839	40–74	50–54	50.2	–	2.3	0.2
	Netherlands	RS-I	6419	55–85+	60–64	40.7	98.9	7.5	1.7
	Netherlands	RS-II	2545	55–85+	55–59	45.4	97.8	6	0.7
	Netherlands	RS-III	3449	45–85+	55–59	43.4	96.4	4.6	0.4
South	France	Montracher-3C	1069	75–85+	80–84	37	100	9.2	2.2
	France	POLA	2196	60–85+	65–69	43.5	–	8.7	1.9
	Portugal	Lousa	3021	55–85+	60–64	43.9	99.3	15.4	1.3
	Portugal	Mira	2975	55–85+	65–69	43.4	99.7	6.9	0.7
	Thessaloniki	Thessaloniki Eye Study	2107	60–85+	65–69	55.6	97.7	–	2.7
Multiple	Italy	PAMDI	853	60–85+	65–69	45.8	100	13.5	2.1
		EUREYE	4753	65–85+	65–69	44.8	–	12.6	3.3

ALIENOR = Antioxydants, Lipids Essentiels, Nutrition et maladies Oculaires Study; AMD = age-related macular degeneration; EPIC = European Prospective Investigation into Cancer; EUREYE = European Eye Study; GHS = Gutenberg Health Study; PAMDI = Prevalence of Age-Related Macular Degeneration in Italy; POLA = Pathologies Oculaires Liées à l'Age Study; RS = Rotterdam Study; – = data not available.

Results

The total study population included in this analysis consisted of 42 080 individuals from 14 studies with a median age of 65–69 years and a slight female predominance (55.8%). The prevalence of all age groups together varied per study between 2.3% and 16.8% for early AMD (total N = 2703) and between 0.2% and 5.6% for late AMD (total N = 664) (Fig 2A and B, available at www.aaojournal.org; to avoid biased estimates only groups larger than 30 individuals are shown; this applied only to the Rotterdam Study 3 age category ≥85 years). Owing to moderate to high heterogeneity ($I^2 \geq 75\%$ in 73 of 141 analyses), which was not related to time trends, we applied a random-effects model for each meta-analysis. This provided a prevalence of early AMD increasing with age from 3.5% (95% confidence interval [CI] 2.1%–5.0%) at 55–59 years to 17.6% (95% CI 13.6%–21.5%) in persons aged ≥85 (Fig 3A, and Table 2, available at www.aaojournal.org). The prevalence of late AMD rose from virtually zero in the youngest age group to 9.8% (95% CI 6.3%–13.3%) for those in the highest age group (Fig 3B). Taking together all people aged ≥70 years, the overall prevalence was 13.2% (95% CI 11.2%–15.1%) for early AMD and 3.0% (95% CI 2.2%–3.9%) for late AMD. We investigated prevalence changes over time by dividing the E3 consortium into studies conducted before and after 2006. The prevalence of early AMD before and after 2006 seemed to rise with age in a similar fashion. For late AMD, a trend of decreasing prevalence was observed for the higher age categories after 2006 (Fig 3C and D). Even after exclusion of the 2 cohorts (Rotterdam Study [RS]-II and European Eye Study [EUREYE]) with the highest prevalences in the highest age category before 2006, results remained similar (data not shown). When we analyzed prevalence data as a function of birth cohort, a relatively stable prevalence of early AMD was visible across all birth cohorts, whereas a decreasing prevalence of late AMD was seen for the more recent birth cohorts (Fig 4A and B).

Gender and Geographic Region

We studied the relation with gender and found no differences in the prevalence of early and late AMD between men and women except for the age category of 85 years and older for late AMD (Fig 5A and B, available at www.aaojournal.org). This category shows a trend for a higher prevalence in women compared to men, although CIs overlap.

To address differential distribution of AMD in Europe, we stratified studies according to 3 regions defined by the United Nations.²⁴ In older individuals, we observed a trend toward a higher prevalence of early AMD in the North (16% in those ≥70 years; 95% CI 14%–17%) compared to the West (12%; 95% CI 10%–14%) and South (14%; 95% CI 10%–17%) (Fig 6A, available at www.aaojournal.org). Likewise, late AMD had the highest prevalence in the North (4.2%; 95% CI 2%–6%) compared to the West (3.1%; 95% CI 2%–4%) and South (3.1%; 95% CI 2%–4%) (Fig 6B, available at www.aaojournal.org). More detailed analyses showed that a frequency difference was only present for CNV (Fig 6C and D, available at www.aaojournal.org); however, CIs of the regional differences overlapped.

Visual Consequences

As most countries implemented anti-VEGF therapy for CNV from 2006 onward, we compared visual impairment from AMD in studies carried out before and after this year. Before 2006,




Figure 3. Meta-analysis of (A) early and (B) late age-related macular degeneration (AMD) in Europe per age category for the participating studies. Meta-analysis of the prevalence of (C) early and (D) late AMD before and after 2006.

54.2% of eyes with GA were visually impaired, and 79.8% of eyes suffering from CNV were visually impaired. From 2006 onward, the proportion of visually impaired eyes remained the same for GA (47.6%; $P = 0.40$), but dropped to 66.2% ($P = 0.026$) for CNV (Fig 7A). This improvement was also observed for the number of bilaterally visually impaired persons; 120 of 345 (34.8%) before 2006 to 75 of 259 (28.9%; $P = 0.13$) after 2006. The largest drop was seen for people aged 80 years and older; 85 of 175 (48.6%) before 2006 to 46 of 132 (34.8%; $P = 0.016$) after 2006 (Fig 7B).

Projections of Age-Related Macular Degeneration in Europe for 2040

Assuming that the prevalence of early and late AMD will remain stable over time, an increase from 15.0 million in 2013 to 21.5 million for early AMD can be expected by 2040. The number of people with late AMD will almost double during this time period, from 2.7 million in 2013 to 4.8 million in 2040.

Assuming a more realistic scenario for which E3 historic data and a decelerating slope were used, we found that the prevalence of




Figure 4. Meta-analysis of early (A) and late (B) age-related macular degeneration in Europe by 10-year birth cohorts.




Figure 7. A, Proportion of visually impaired eyes within each subgroup of late age-related macular degeneration (AMD). The proportion of visually impaired eyes remained the same for geographic atrophy (47.6%; $P = 0.4$), but dropped to 66.2% ($P = 0.026$) for choroidal neovascularization after 2006. B, Proportion of persons with late AMD with bilateral visual impairment before and after 2006 ($P = 0.016$). * $P < 0.05$.

early AMD will first decrease and then slightly increase between 2013 and 2040. The model estimated that the number of people with early AMD would remain almost the same: from 15.0 million in 2013 to 14.9 million in 2040. This model also displayed that the number of people with late AMD in Europe will increase from 2.7 million in 2013 to 3.9 million by 2040 (Fig 8).

Discussion

Age-Related Macular Degeneration Prevalence and Its Time Trends

Our study provides insight into the prevalence of both early and late AMD in Europe. Based on meta-analyzed data from 14 population-based cohort studies included in the E3 consortium, the overall prevalence of early and late AMD was 13.2% and 3.0%, respectively, in the age category ≥ 70 years. These estimates are comparable to those among persons of European descent living in other continents.^{4,25}

Our data show a trend toward a slightly decreasing prevalence of AMD in the older age categories. It is unlikely that this is explained by differential mortality in AMD patients before and after 2006, although studies have shown conflicting results on death as a competing risk factor for AMD, and we cannot exclude that this plays a role.^{26–28} The decreasing trend in time has also been observed in the Beaver Dam Eye Study, indicating that these trends are not confined to Europe.²⁹ Decreasing rates have also been observed for other aging disorders such as cardiovascular disease and dementia,^{30–33} and may be related to improved lifestyle among the elderly^{34–36}; for example, the number of smokers declined by 30.5% from 1990 to 2010 in Europe.³⁷ Taken together, the decline in prevalence suggests that the increases in the number of AMD patients may not be as substantial as previous prediction studies suggested.³⁸

Gender and Geographic Regions

Our data showed no difference in the prevalence of early and late AMD with respect to gender. In the oldest age category of 85 years and older, women seemed to have a

higher prevalence of late AMD, but detailed analysis showed that this was mostly owing to imprecision of the estimate in men, caused by a lower number of men in this age group (Fig 9, available at www.aaojournal.org). This has also been observed in other studies.^{7,39}

As for regional differences, we noticed that the northern region of Europe showed a slightly higher prevalence of early and late AMD. This trend was the result of a higher prevalence of CNV in the north. Our findings are in concordance with the results previously published by the Tromsø Eye Study⁴⁰ but are in contrast with other studies performed in the north of Europe finding a higher prevalence of GA (EUREYE, Reykjavik Eye Study, and Oslo Macular Study).^{41–43} Considering the larger sample size and high response rate of the Tromsø Eye Study compared with the other studies, these findings might be more legitimate. No consistent differences were observed for the western and southern regions of Europe.

Visual Consequences

The proportion of eyes affected by CNV that were visually impaired was reduced after the year 2006. Unfortunately, our study lacked actual data on interventions for CNV, but it is likely that the reduction is attributable to the use of anti-VEGF injections, which were introduced as a therapy for CNV in Europe from 2006 onward.¹⁸ This notion is supported by findings from clinical trials^{44,45} and other studies, which show an up to 2-fold decrease in legal blindness due to AMD after 2006.^{14,15,46,47} The public campaigns that were initiated after the introduction of anti-VEGF have undoubtedly contributed to the reduction of visual loss, as they made elderly persons more aware of the symptoms and stimulated prompt therapy.^{48,49}

Projections of Age-Related Macular Degeneration in Europe

It is unclear whether the prevalence of AMD will decrease even more in the coming years, but an increase is not likely to be expected. Therefore, we projected the estimated number of AMD-affected persons until the year 2040 based on 2 different scenarios: 1 based on stable prevalence and 1




Figure 8. Predicted number of persons with age-related macular degeneration (AMD) in years 2013–2040 as a function of 2 prevalence scenarios.

following the trend of declining prevalences. The results of the first scenario suggests that the absolute number of persons with late AMD will increase by 2.1 million, a 1.5-times increase. A Norwegian study predicted, under the assumption of a stable prevalence, the same relative increase of affected subjects, with a total of 328 000 cases of late AMD in Scandinavia by 2040.^{5,8} A study in the United States calculated a 2.2-times increase in absolute numbers and estimated a total number of affected subjects to be 3.8 million by 2050.^{5,8} Worldwide projections have shown a doubling of late AMD and an increase of 9 million cases by 2040.⁴

The second scenario was based on declining rates, and showed a small increase in the number of people with early AMD, from 14 million in 2016 to 14.9 million by 2040, and a larger relative increase in the number of people with late AMD, from 2.7 million in 2016 to 3.9 million by 2040. Considering the declining rates of smoking and implementation of healthier diets in elderly persons, the second projection may be more legitimate.

Study Limitations

A limitation to this E3 consortium meta-analysis is the heterogeneity across studies regarding study design and inclusion criteria. For example, age at inclusion and method of recruitment varied between studies. Although in every study AMD was classified according to the Rotterdam Classification, studies differed in AMD grading, especially for pigmentary changes and drusen size. Given the heterogeneity, we therefore performed a random-effects meta-analysis for both early and late AMD. Furthermore, patient management and access to health care may have differed between study sites, resulting in differences in preventive and treatment options.^{50,51}

When data collection started in 1990, fundus photography was the gold standard for grading AMD. Since 1990, imaging techniques evolved rapidly, greatly improving the diagnosis of AMD features with non-invasive techniques such as optical coherence tomography, autofluorescence, and near-infrared photographs. In addition, multimodal imaging better visualizes edema and subtle changes resulting from CNV, which may not be so apparent when the patient was treated with anti-VEGF therapy.^{52,53} Although macular edema due to sub-retinal neovascularization often coincides with prominent retinal changes such as hemorrhages or hard exudates, our data may have underestimated the true prevalence of CNV.⁵³

In summary, this study estimates the prevalence of early and late AMD per age category in Europe over the past two decades. Prevalence of both these forms remained stable or decreased slightly. Nevertheless, we observed a significant reduction in the proportion of visually impaired eyes attributable to CNV after 2006. Unfortunately, due to the aging population, the number of people with AMD will increase during the next decades, indicating a continuous need to develop comprehensive modalities for prevention and treatment of AMD.

Appendix

The E3 Consortium[§]

First Name	Last Name	Institution	City	Country
Niyazi	Acar	Inra-University of Burgundy	Dijon	France
Eleftherios	Anastosopoulos	University of Thessaloniki	Thessaloniki	Greece
Augusto	Azuara-Blanco	Queen's University	Belfast	UK
Arthur	Bergen	Netherlands Institute for Neurosciences-KNAW	Amsterdam	Netherlands
Geir	Bertelsen	University of Tromsø	Tromsø	Norway
Christine	Binquet	University Hospital of Dijon	Dijon	France
Alan	Bird	Moorfields Eye Hospital	London	UK
Lionel	Brétillon	Inra-University of Burgundy	Dijon	France
Alain	Bron	University Hospital of Dijon	Dijon	France
Gabrielle	Buitendijk	Erasmus Medical Center	Rotterdam	Netherlands
Maria Luz	Cachulo	AIBILI/CHUC	Coimbra	Portugal
Usha	Chakravarthy	Queen's University	Belfast	UK
Michelle	Chan	UCL Institute of Ophthalmology	London	UK
Petrus	Chang	University of Bonn	Bonn	Germany
Johanna	Colijn	Erasmus Medical Center	Rotterdam	Netherlands
Audrey	Cougnard-Grégoire	University of Bordeaux Segalen	Bordeaux	France

(Continued)

(Continued.)

First Name	Last Name	Institution	City	Country
Catherine	Creuzot-Garcher	University Hospital of Dijon	Dijon	France
Philippa	Cumberland	UCL Institute of Child Health	London	UK
José	Cunha-Vaz	AIBILI/CHUC	Coimbra	Portugal
Vincent	Daïen	Inserm U1061	Montpellier	France
Gabor	Deak	Medical University of Vienna	Vienna	Austria
Cécile	Delcourt	University of Bordeaux Segalen	Bordeaux	France
Marie-Noëlle	Delyfer	University of Bordeaux Segalen	Bordeaux	France
Anneke	den Hollander	Radboud University	Nijmegen	Netherlands
Martha	Dietzel	University of Muenster	Muenster	Germany
Maja Gran	Erke	University of Tromsø	Tromsø	Norway
Sascha	Fausser	University Eye Hospital	Cologne	Germany
Robert	Finger	University of Bonn	Bonn	Germany
Astrid	Fletcher	London School of Hygiene and Tropical Medicine	London	UK
Paul	Foster	UCL Institute of Ophthalmology	London	UK
Panayiota	Founti	University of Thessaloniki	Thessaloniki	Greece
Arno	Göbel	University of Bonn	Bonn	Germany
Theo	Gorgels	Netherlands Institute for Neurosciences-KNAW	Amsterdam	Netherlands
Jakob	Grauslund	University of Southern Denmark	Odense	Denmark
Franz	Grus	University Medical Center Mainz	Mainz	Germany
Christopher	Hammond	King's College	London	UK
Catherine	Helmer	University of Bordeaux Segalen	Bordeaux	France
Hans-Werner	Hense	University of Muenster	Muenster	Germany
Manuel	Hermann	University Eye Hospital	Cologne	Germany
René	Hoehn	University Medical Center	Mainz	Germany
Ruth	Hogg	Queen's University	Belfast	UK
Frank	Holz	University of Bonn	Bonn	Germany
Carel	Hoyng	Radboud University	Nijmegen	Netherlands
Nomdo	Jansonius	Erasmus Medical Center	Rotterdam	Netherlands
Sarah	Janssen	Netherlands Institute for Neurosciences-KNAW	Amsterdam	Netherlands
Anthony	Khawaja	UCL Institute of Ophthalmology	London	UK
Caroline	Klaver	Erasmus Medical Center	Rotterdam	Netherlands
Jean-François	Korobelnik	University of Bordeaux Segalen	Bordeaux	France
Julia	Lamparter	University Medical Center Mainz	Mainz	Germany
Mélanie	Le Goff	University of Bordeaux Segalen	Bordeaux	France
Sergio	Leal	AIBILI/CHUC	Coimbra	Portugal
Yara	Lechanteur	Radboud University	Nijmegen	Netherlands
Terho	Lehtimäki	Pirkanmaa Hospital District	Tampere	Finland
Andrew	Lotery	University of Southampton	Southampton	UK
Irene	Leung	Moorfields Eye Hospital	London	UK
Matthias	Mauschitz	University of Bonn	Bonn	Germany
Bénédictte	Merle	University of Bordeaux Segalen	Bordeaux	France
Verena	Meyer zu Westrup	University of Muenster	Muenster	Germany
Edoardo	Midena	University of Padova	Padova	Italy
Stefania	Miotto	University of Padova	Padova	Italy
Alireza	Mirshahi	University Medical Center	Mainz	Germany
Sadek	Mohan-Saïd	Institut de la Vision	Paris	France
Michael	Mueller	Pirkanmaa Hospital District	Tampere	Finland
Alyson	Muldrew	Queen's University	Belfast	UK
Sandrina	Nunes	AIBILI/CHUC	Coimbra	Portugal
Konrad	Oexle	Institut of Human Genetics	Munich	Germany
Tunde	Peto	Queen's University	Belfast	UK
Stefano	Piermarocchi	University of Padova	Padova	Italy
Elena	Prokofyeva	Scientific Institute of Public Health (WIV-ISP), Federal Agency for Medicines and Health Products	Brussels	Belgium
Jugnoo	Rahi	UCL Institute of Ophthalmology	London	UK
Olli	Raitakari	Pirkanmaa Hospital District	Tampere	Finland
Luisa	Ribeiro	AIBILI/CHUC	Coimbra	Portugal
Marie-Bénédictte	Rougier	University of Bordeaux Segalen	Bordeaux	France
José	Sahel	Institut de la Vision	Paris	France
Aggeliki	Salonikiou	University of Thessaloniki	Thessaloniki	Greece
Clarisa	Sanchez	Radboud University	Nijmegen	Netherlands

(Continued)

(Continued.)

First Name	Last Name	Institution	City	Country
Steffen	Schmitz-Valckenberg	University of Bonn	Bonn	Germany
Cédric	Schweitzer	University of Bordeaux Segalen	Bordeaux	France
Tatiana	Segato	University of Padova	Padova	Italy
Jasmin	Shehata	Medical University of Vienna	Vienna	Austria
Rufino	Silva	AIBILI/CHUC	Coimbra	Portugal
Giuliana	Silvestri	Queen's University	Belfast	UK
Christian	Simader	Medical University of Vienna	Vienna	Austria
Eric	Souied	University Hospital of Créteil	Créteil	France
Henriet	Springelkamp	Erasmus Medical Center	Rotterdam	Netherlands
Robyn	Tapp	Pirkanmaa Hospital District	Tampere	Finland
Fotis	Topouzis	University of Thessaloniki	Thessaloniki	Greece
Virginie	Verhoeven	Erasmus Medical Center	Rotterdam	Netherlands
Therese	Von Hanno	University of Tromsø	Tromsø	Norway
Stela	Vujosevic	University of Padova	Padova	Italy
Katie	Williams	King's College London	London	UK
Christian	Wolfram	University Medical Center	Mainz	Germany
Jennifer	Yip	UCL Institute of Ophthalmology	London	UK
Jennyfer	Zerbib	University Hospital of Créteil	Créteil	France
Isabella	Zwiener	University Medical Center	Mainz	Germany

The EYE-RISK Consortium[‡]

Soufiane Ajana,¹ Blanca Arango-Gonzalez,² Verena Arndt,³ Vaibhav Bhatia,⁴ Shomi S. Bhattacharya,⁴ Marc Biarnés,⁵ Anna Borrell,⁵ Sebastian Bühren,⁶ Sofia M. Calado,⁴ Johanna M. Colijn,^{7,8} Audrey Cournard-Grégoire,¹ Sascha Dammeier,² Eiko K. de Jong,⁹ Berta De la Cerda,⁴ Cécile Delcourt,¹ Anneke I. den Hollander,^{9,10} Francisco J. Diaz-Corrales,⁴ Sigrid Diether,² Eszter Emri,¹¹ Tanja Endermann,³ Lucia L. Ferraro,⁵ Míriam Garcia,⁵ Thomas J. Heesterbeek,⁹ Sabina Honisch,² Carel B. Hoyng,⁹ Eveline Kersten,⁹ Ellen Kilger,² Caroline C.W. Klaver,^{7,8,9} Hanno Langen,¹² Imre Lengyel,¹¹ Phil Luthert,¹³ Cyrille Maugeais,¹² Magda Meester-Smoor,^{7,8} Bénédicte M.J. Merle,¹ Jordi Monés,⁵ Everson Nogoceke,¹² Tunde Peto,¹⁴ Frances M. Pool,¹⁵ Eduardo Rodríguez,⁵ Marius Ueffing,^{2,16} Karl U. Ulrich Bartz-Schmidt,^{2,16} Elisabeth M. van Leeuwen,^{7,8} Timo Verzijden,^{7,8} Markus Zumbansen¹⁷

¹University Bordeaux, Inserm, Bordeaux Population Health Research Center, Team LEHA, UMR 1219, Bordeaux, France.

²Centre for Ophthalmology, Institute for Ophthalmic Research, Eberhard Karls University Tübingen, University Clinic Tübingen, Tübingen, Germany.

³Assay Development, AYOXXA Biosystems GmbH, Cologne, Germany.

⁴Department of Regeneration and Cell Therapy, Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), Seville, Spain.

⁵Barcelona Macula Foundation, Barcelona, Spain.

⁶Business Development, AYOXXA Biosystems GmbH, Cologne, Germany.

⁷Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands.

⁸Department of Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands.

⁹Department of Ophthalmology, Radboud University Medical Center, Nijmegen, Netherlands.

¹⁰Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.

¹¹Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.

¹²Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

¹³Institute of Ophthalmology, University College London, London, United Kingdom.

¹⁴Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.

¹⁵Ocular Biology, UCL Institute of Ophthalmology, London, United Kingdom.

¹⁶Department of Ophthalmology, University Medical Centre Tübingen, Tübingen, Germany.

¹⁷Research and Development, AYOXXA Biosystems GmbH, Cologne, Germany.

References

1. Bourne RR, Jonas JB, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. *Br J Ophthalmol*. 2014;98(5):629-638.
2. de Jong PT. Age-related macular degeneration. *N Engl J Med*. 2006;355(14):1474-1485.
3. Ozaki E, Campbell M, Kiang AS, et al. Inflammation in age-related macular degeneration. *Adv Exp Med Biol*. 2014;801:229-235.
4. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob Health*. 2014;2(2):e106-e116.
5. Lindekleiv H, Erke MG. Projected prevalence of age-related macular degeneration in Scandinavia 2012-2040. *Acta Ophthalmol*. 2013;91(4):307-311.
6. Bauer P, Barthelmes D, Kurz M, et al. The potential effect of population development, smoking and antioxidant supplementation on the future epidemiology of age-related

- macular degeneration in Switzerland. *Klin Monbl Augenheilkd*. 2008;225(5):376-379.
7. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. *Arch Ophthalmol*. 2004;122(4):564-572.
 8. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. *Arch Ophthalmol*. 2009;127(4):533-540.
 9. Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. *Br J Ophthalmol*. 2012;96(5):752-756.
 10. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. *Arch Ophthalmol*. 1998;116(5):653-658.
 11. Korb CA, Kottler UB, Wolfram C, et al. Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg Health Study. *Graefes Arch Clin Exp Ophthalmol*. 2014;252(9):1403-1411.
 12. Hoeg TB, Ellervik C, Buch H, et al. Danish Rural Eye Study: epidemiology of adult visual impairment. *Ophthalmic Epidemiol*. 2016;23(1):53-62.
 13. Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. *Ophthalmic Res*. 2012;47(4):171-188.
 14. Claessen H, Genz J, Bertram B, et al. Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. *Eur J Epidemiol*. 2012;27(7):519-524.
 15. Skaat A, Chetrit A, Belkin M, et al. Time trends in the incidence and causes of blindness in Israel. *Am J Ophthalmol*. 2012;153(2):214-221.e1.
 16. Delcourt C, Korobelnik JF, Buitendijk GH, et al. Ophthalmic epidemiology in Europe: the "European Eye Epidemiology" (E3) consortium. *Eur J Epidemiol*. 2016;31(2):197-210.
 17. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med*. 2004;351(27):2805-2816.
 18. Wolf S. Current status of anti-vascular endothelial growth factor therapy in Europe. *Jpn J Ophthalmol*. 2008;52(6):433-439.
 19. Cachulo Mda L, Lains I, Lobo C, et al. Age-related macular degeneration in Portugal: prevalence and risk factors in a coastal and an inland town. The Coimbra Eye Study - Report 2. *Acta Ophthalmol*. 2016;94(6):e442-e453.
 20. Cachulo Mda L, Lobo C, Figueira J, et al. Prevalence of Age-Related Macular Degeneration in Portugal: The Coimbra Eye Study - Report 1. *Ophthalmologica*. 2015;233(3-4):119-127.
 21. van Leeuwen R, Chakravarthy U, Vingerling JR, et al. Grading of age-related maculopathy for epidemiological studies: is digital imaging as good as 35-mm film? *Ophthalmology*. 2003;110(8):1540-1544.
 22. Eurostatv3.1.15-20160425-5608-PROD_EUROBASE. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=proj_15npsms&lang=en; Accessed February 8, 2016.
 23. Haldane JB. The estimation and significance of the logarithm of a ratio of frequencies. *Ann Hum Genet*. 1956;20(4):309-311.
 24. Division UNSComposition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. Available at: <https://unstats.un.org/unsd/methodology/m49>; Accessed March 18, 2015
 25. Klein R, Chou CF, Klein BE, et al. Prevalence of age-related macular degeneration in the US population. *Arch Ophthalmol*. 2011;129(1):75-80.
 26. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. *Ophthalmology*. 2003;110(7):1292-1296.
 27. Wang J, Xue Y, Thapa S, et al. Relation between age-related macular degeneration and cardiovascular events and mortality: a systematic review and meta-analysis. *Biomed Res Int*. 2016;2016:8212063.
 28. McGuinness MB, Karahalios A, Kasza J, et al. Survival bias when assessing risk factors for age-related macular degeneration: a tutorial with application to the exposure of smoking. *Ophthalmic Epidemiol*. 2017:1-10.
 29. Klein R, Knudtson MD, Lee KE, et al. Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study. *Ophthalmology*. 2008;115(9):1460-1467.
 30. Crimmins EM, Hayward MD, Hagedorn A, et al. Change in disability-free life expectancy for Americans 70-years-old and older. *Demography*. 2009;46(3):627-646.
 31. Koch MB, Davidsen M, Andersen LV, et al. Increasing prevalence despite decreasing incidence of ischaemic heart disease and myocardial infarction. A national register based perspective in Denmark, 1980-2009. *Eur J Prev Cardiol*. 2015;22(2):189-195.
 32. Davies AR, Smeeth L, Grundy EM. Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996-2005. *Eur Heart J*. 2007;28(17):2142-2147.
 33. Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of dementia over three decades in the Framingham Heart Study. *N Engl J Med*. 2016;374(6):523-532.
 34. Plessz M, Gueguen A, Goldberg M, et al. Ageing, retirement and changes in vegetable consumption in France: findings from the prospective GAZEL cohort. *Br J Nutr*. 2015;114(6):979-987.
 35. Pot GK, Prynne CJ, Almoosawi S, et al. Trends in food consumption over 30 years: evidence from a British birth cohort. *Eur J Clin Nutr*. 2015;69(7):817-823.
 36. Jungjohann SM, Luhrmann PM, Bender R, et al. Eight-year trends in food, energy and macronutrient intake in a sample of elderly German subjects. *Br J Nutr*. 2005;93(3):361-378.
 37. OECD (2013), Change in smoking rates: Percentage change over the period 1990-2010 or latest available period, in OECD Factbook 2013, OECD Publishing, Paris. DOI: <http://dx.doi.org/10.1787/factbook-2013-graph252-en>.
 38. Huang GH, Klein R, Klein BE, Tomany SC. Birth cohort effect on prevalence of age-related maculopathy in the Beaver Dam Eye Study. *Am J Epidemiol*. 2003;157(8):721-729.
 39. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. *Ophthalmology*. 1995;102(10):1450-1460.
 40. Erke MG, Bertelsen G, Peto T, et al. Prevalence of age-related macular degeneration in elderly Caucasians: the Tromso Eye Study. *Ophthalmology*. 2012;119(9):1737-1743.
 41. Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). *Arch Ophthalmol*. 2006;124(4):529-535.
 42. Jonasson F, Arnarsson A, Sasaki H, et al. The prevalence of age-related maculopathy in Iceland: Reykjavik eye study. *Arch Ophthalmol*. 2003;121(3):379-385.
 43. Bjornsson OM, Syrdalen P, Bird AC, et al. The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular study. *Acta Ophthalmol Scand*. 2006;84(5):636-641.

44. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med.* 2011;364(20):1897-1908.
45. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. *Ophthalmology.* 2009;116(9):1731-1739.
46. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. *Am J Ophthalmol.* 2012;153(2):209-213.e2.
47. Granstam E, Westborg I, Barkander A, et al. Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration - a population- and register-based study from northern Sweden. *Acta Ophthalmol.* 2016;94(7):646-651.
48. Heraghty J, Cummins R. A layered approach to raising public awareness of macular degeneration in Australia. *Am J Public Health.* 2012;102(9):1655-1659.
49. Bertram B, Gante C, Hilgers RD. Increase in examinations for cataracts, glaucoma, diabetic retinopathy and age-related macular degeneration: Comparative cross-sectional study between 2010 and 1997 in ophthalmological practices [in German]. *Ophthalmologe.* 2014;111(8):757-764
50. Marques AP, Macedo AF, Perelman J, et al. Diffusion of anti-VEGF injections in the Portuguese National Health System. *BMJ Open.* 2015;5(11):e009006.
51. Keenan TD, Wotton CJ, Goldacre MJ. Trends over time and geographical variation in rates of intravitreal injections in England. *Br J Ophthalmol.* 2012;96(3):413-418.
52. Yehoshua Z, Gregori G, Sadda SR, et al. Comparison of drusen area detected by spectral domain optical coherence tomography and color fundus imaging. *Invest Ophthalmol Vis Sci.* 2013;54(4):2429-2434.
53. Wang YT, Tadarati M, Wolfson Y, et al. Comparison of prevalence of diabetic macular edema based on monocular fundus photography vs optical coherence tomography. *JAMA Ophthalmol.* 2016;134(2):222-228.

Footnotes and Financial Disclosures

Originally received: January 2, 2017.

Final revision: May 2, 2017.

Accepted: May 26, 2017.

Available online: July 14, 2017.

Manuscript no. 2016-1147.

¹ Department of Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands.

² Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands.

³ Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.

⁴ Federal Agency for Medicines and Health Products, Brussels, Belgium.

⁵ Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal.

⁶ Department of Ophthalmology, Coimbra Hospital and University Center (CHUC), Coimbra, Portugal.

⁷ Association for Innovation and Biomedical Research on Light and Image (AIBIL), Coimbra, Portugal.

⁸ Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.

⁹ NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.

¹⁰ University Bordeaux, Inserm, Bordeaux Population Health Research Center, Team LEHA, Bordeaux, France.

¹¹ Department of Ophthalmology, University Medical Center Mainz, Mainz, Germany.

¹² UiT The Arctic University of Norway/University Hospital of North Norway, Tromsø, Norway.

¹³ Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.

¹⁴ Department of Ophthalmology, University Hospital, Eye and Nutrition Research Group, Dijon, France.

¹⁵ Department of Ophthalmology, Aristotle University of Thessaloniki AHEPA Hospital, Thessaloniki, Greece.

¹⁶ Integrative Epidemiology, UCL Institute of Ophthalmology, London, United Kingdom.

¹⁷ CHU de Bordeaux, Service d'Ophtalmologie, Bordeaux, France.

¹⁸ Department of Ophthalmology, University of Padova, Padova, Italy.

¹⁹ Netherlands Institute of Neurosciences (NIN), Institute of the Royal Netherlands Academy of Arts and Sciences (KNAW), Department of Ophthalmology, AMC, Amsterdam and LUMC, Leiden, Netherlands.

²⁰ Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.

²¹ Department of Ophthalmology, Radboud University Medical Center, Nijmegen, Netherlands.

*Drs Colijn and Buitendijk contributed equally to this manuscript.

‡§See list in Appendix.

Financial Disclosure(s):

C.D.: Consultant — Allergan, Bausch & Lomb, Laboratoires, Théa, Novartis, and Roche.

R.S.: Consultant — Alimera, Allergan, Alcon, Bayer, Novartis, and Théa.

The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists.

The Gutenberg Health Study (GHS) is funded through the government of Rhineland-Palatinate ("Stiftung Rheinland-Pfalz für Innovation," contract AZ 961-386261/733), the research programs "Wissen schafft Zukunft" and "Center for Translational Vascular Biology (CTVB)" of the Johannes Gutenberg-University of Mainz, and its contract with Boehringer Ingelheim and PHILIPS Medical Systems, including an unrestricted grant for the GHS. The authors thank all study participants for their willingness to provide data for this research project and we are indebted to all coworkers for their enthusiastic commitment.

H2020-RIA, EYE-RISK, grant number: 634479. Uitzicht grant number: 2015-36, Oogfonds, MaculaFonds, LSBS, Novartis Fonds. The sponsors and funding organization had no role in the design or conduct of this research.

Author Contributions:

Conception and design: Khawaja, Korb, Erke, Piermarocchi, Creuzot-Garcher, Pfeiffer, Delcourt, Klaver

Analysis and interpretation: Colijn, Buitendijk, Prokofyeva, Alves, Cachulo, Khawaja, Cougnard-Gregoire, Merle, Korb, Erke, Bron, Anastasopoulos, Segato, Piermarocchi, Vingerling, Topouzis, Creuzot-Garcher, Pfeiffer, Silva, Korobelnik, Delcourt, Klaver

Data collection: Colijn, Buitendijk, Cachulo, Khawaja, Korb, Erke, Bron, Anastasopoulos, Meester-Smoor, Segato, Piermarocchi, de Jong, Vingerling, Topouzis, Creuzot-Garcher, Bertelsen, Fletcher, Foster, Silva, Delcourt, Klaver

Obtained funding: Not applicable

Overall responsibility: Colijn, Buitendijk, Prokofyeva, Khawaja, Cougnard-Gregoire, Merle, Korb, Erke, Anastasopoulos, Topouzis, Bertelsen, Pfeiffer, Fletcher, Foster, Silva, Korobelnik, Delcourt, Klaver


Abbreviations and Acronyms:

AMD = age-related macular degeneration; **CI** = confidence interval; **CNV** = choroidal neovascularization; **E3** = European Eye Epidemiology (consortium); **EPIC** = European Prospective Investigation into Cancer and Nutrition; **EUREYE** = European Eye Study; **GA** = geographic atrophy; **RS** = Rotterdam Study; **UK** = United Kingdom; **VEGF** = vascular endothelial growth factor.

Correspondence:

Caroline C.W. Klaver, MD, PhD, Department of Ophthalmology, Erasmus Medical Centre, P.O. Box 2040, NL-3000 CA Rotterdam, the Netherlands. E-mail: c.c.w.klaver@erasmusmc.nl.

Pictures & Perspectives



Wyburn-Mason Incidentally Diagnosed on Evaluation of Eye Redness

A 10-year-old boy presented with a 1-week history of painless left eye injection without visual changes. He also acknowledged intermittent headaches and right-sided weakness. Dilated examination of the left eye revealed dilated, tortuous retinal vasculature (Fig 1A). T2-weighted brain magnetic resonance imaging (MRI) with contrast demonstrated a large left arteriovenous malformation (arrow) centered on the posterior limb of the internal capsule with involvement of the left basal ganglia and thalamus (Fig 1B). These collective findings are consistent with a diagnosis of Wyburn-Mason syndrome. The patient's left eye injection was likely unrelated because there was no evidence of a carotid-cavernous fistula or venous outflow obstruction. (Magnified version of Fig 1A-B is available online at www.aaojournal.org).

CHRISTINA Y. WENG, MD, MBA¹

SARAH A. LOGAN, MD^{1,2}

CHARLENE CROCKETT, MD^{1,2}

¹Baylor College of Medicine, Department of Ophthalmology-Cullen Eye Institute, Houston, Texas; ²Texas Children's Hospital, Houston, Texas